- Faculty
- Health
- In the News
Ph I/II Study of NVL-655 Patients with Advanced NSCLC and Other Solid Tumors
Misako Nagasaka
A Study On:
- Small Intestine
- Other Respiratory and Intrathoracic Organs
- Soft Tissue
- Mycosis Fungoides
- Ovary
- Colon
- Larynx
- Lung
- Other Female Genital
- Lip, Oral Cavity and Pharynx
- Pancreas
- Urinary Bladder
- Brain and Nervous System
- Breast
- Rectum
- Anus
- Prostate
- Kidney
- Melanoma, Skin
- Kaposi's Sarcoma
- Esophagus
- Thyroid
- Unknown Sites
- Stomach
- Other Digestive Organ
- Bones and Joints
- Cervix
- Corpus Uteri
- Other Urinary
- Liver
- Other Skin
- Other Male Genital
- Eye and Orbit
- Other Endocrine System
- Ill-Defined Sites
Status:
- Open
Eligibility
Adult
Interested in joining this trial?
Official Title
A Phase I/II Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
Details
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors.
Phase 1 will determine the RP2D and, if applicable, the MTD of NVL-655 in patients with advanced ALK+ solid tumors.
Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of NVL-655 at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of NVL-655 in patients with advanced ALK-positive NSCLC and other solid tumors.
Eligibility
You can join if...
Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.
Inclusion Criteria:
- Age = or > 18 years
- Phase 1: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented ALK rearrangement or activating ALK mutation.
- Phase 2
a. Cohorts 2a, 2b, and 2c: Histologically or cytologically confirmed locally advanced or metastatic NSCLC with a documented ALK rearrangement
b. Cohort 2d: histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented ALK rearrangement or activating ALK mutation - Phase 1: Must have evaluable disease (target or nontarget) according to RECIST 1.1 Phase 2: Must have measurable disease according to RECIST 1.1
- Adequate organ function and bone marrow reserve
Exclusion criteria:
- Patient's cancer has a known oncogenic driver alteration other than ALK.
- Known allergy/hypersensitivity to excipients of NVL-655.
- Major surgery within 4 weeks of the study entry
- Ongoing or anticancer therapy
- Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.
Get in touch with our study team
News & Events
UCI Health enrolls patient in first U.S. study of medical device for erectile dysfunction Sickle cell disease treatment nearing FDA approval - Faculty
- Health
- In the News
His GERD is now a distant memory - Faculty
- Health
- In the News